Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New IV antibiotic launched for treating UTIs

  • Comment

A new antibiotic to treat complicated intra-abdominal and urinary tract infections, and acute pyelonephritis has been launched in the UK.

Pharmaceutical company MSD has today announced the availability of ceftolozane/tazobactam (Zerbaxa) in the UK.

It is a new intravenous antibiotic for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections in hospital settings. It is intended to offer an alternative to carbapenems.

Ceftolozane/tazobactam (1g/0.5g) is a combination product consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium.

It is administered every eight hours by an intravenous infusion lasting one hour with the treatment length normally lasting four to 14 days.

Professor David Livermore, from the University of East Anglia, said: “It’s a new antibiotic that treats Gram-negative infections, where a lot of resistance problems are now accumulating.

“Its activity against Pseudomonas is especially important,” he added.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.